
Dec 22, 2024, 13:11
Akhil Santhosh: Important changes in the latest ESMO BTC guidelines
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre & Research Institute, shared a post on X:
“Important changes in the latest ESMO BTC guidelines:
- Removal of Infigratinib in the FGFR rearranged setting.
- Inclusion of Zanidatamab (Herizon Btc 01) and Trastuzumab deruxtecan Destiny pan tumour 02 for Her2 amplified/overexpressed BTC.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 04:55
Mar 29, 2025, 04:16
Mar 28, 2025, 20:11
Mar 28, 2025, 19:58
Mar 28, 2025, 19:38